Literature DB >> 12895182

Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.

Katrina Kokjohn1, Mary Bradley, Brian Griffiths, Mahmoud Ghannoum.   

Abstract

BACKGROUND: In many instances, a cutaneous fungal infection may exist concomitantly with bacterial involvement. In this study we compared the in vitro activity of three antifungal agents against the dermatophytes, yeasts and bacteria recovered most commonly from cutaneous mycoses and bacterial infections.
METHODS: Using a microdilution method adapted from the National Committee for Clinical Laboratory Standards (NCCLS), we determined the minimum inhibitory concentrations (MICs) of ciclopirox olamine, econazole nitrate and butenafine HCl against a panel of dermatophyte fungi and yeasts (n = 39) and bacterial isolates (n = 45).
RESULTS: All three antifungals demonstrated comparable activity against the dermatophytes tested, with a MIC range of 0.03-0.25 micro g/ml for ciclopirox, < 0.001-0.25 micro g/ml for econazole and 0.03-0.25 micro g/ml for butenafine. For yeasts, ciclopirox showed activity against all isolates, with an MIC range of 0.001-0.25 micro g/ml, whereas econazole had a broader range of 0.125-> 0.5 micro g/ml. Butenafine displayed limited activity against the yeast Candida albicans and no activity against Malassezia furfur. For the antibacterial activity studies, ciclopirox demonstrated activity against all isolates tested with a range of 0.06-2 micro g/ml, while econazole showed activity against Gram-positive bacteria only, with a MIC range of 0.004-0.25 micro g/ml. Butenafine HCl had a limited activity against bacterial isolates tested, showing activity against beta-hemolytic Streptococcus Group A and Corynebacterium only. Neither econazole nitrate nor butenafine HCl demonstrated activity against any of the Gram-negative strains evaluated in this study.
CONCLUSIONS: The data suggest that ciclopirox olamine has the broadest in vitro activity, in comparison to econazole and butenafine HCl, against bacteria, yeasts and bacteria. These findings may have implications in the use of these antimycotics in the treatment of mixed cutaneous infections where bacteria or yeasts are present in addition to dermatophytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895182     DOI: 10.1046/j.1365-4362.42.s1.4.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.

Authors:  Mahmoud Ghannoum; Nancy Isham; Jacqueline Herbert; William Henry; Sam Yurdakul
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

Review 2.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.

Authors:  Alessandro Subissi; Daniela Monti; Giuseppe Togni; Federico Mailland
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

3.  Econazole-releasing porous space maintainers for fungal periprosthetic joint infection.

Authors:  Alexander M Tatara; Allison J Rozich; Panayiotis D Kontoyiannis; Emma Watson; Nathaniel D Albert; George N Bennett; Antonios G Mikos
Journal:  J Mater Sci Mater Med       Date:  2018-05-11       Impact factor: 3.896

4.  Lateral drug diffusion in human nails.

Authors:  Biji B Palliyil; Cong Li; Suzan Owaisat; David B Lebo
Journal:  AAPS PharmSciTech       Date:  2014-06-27       Impact factor: 3.246

5.  A preformulation strategy for the selection of penetration enhancers for a transungual formulation.

Authors:  Biji Palliyil; David B Lebo; Pankil R Patel
Journal:  AAPS PharmSciTech       Date:  2013-04-10       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.